MYOGEM LAUNCHES IN 2019 THE CLINICAL TRIAL OF THE FOOD SUPPLEMENT MYODM IN MYOTONIC DISTROPHY TYPE 1 (DM1)
DM1 IS A NEUROMUSCULAR RARE DISEASE AFFECTING ONE MILLION PEOPLE WORLDWIDE
Mollet del Vallès (Barcelona), 12 September 2019
Myogem Health Company S.L. and its project “New food for special medical purposes for the nutritional management of Myotonic Dystrophy type 1” have been awarded with two Seals of Excellence and funding by the European Commission in the Horizon 2020 SME Instrument Phase 1 research program to perform the clinical trial of the food supplement MYODM. The trial will be carried out at the Hospital Universitario Donostia, Biodonostia Institute.
DM1 or Steinert’s disease is a complex neuromuscular multisystemic genetic disease, highly limiting the quality of life of almost one million people worldwide. There is currently no cure for DM1.
Upon the clinical trial, Myogem aims to boost the current food supplement into a food for special medical purposes, foods specially prepared or formulated and intended for the dietary management of patients, under medical supervision.
The clinical trial will be conducted by Dr. Roberto Fernández Torrón, neurologist with an extensive experience in DM1, in the Neurology service of the Hospital Universitario Donostia, Biodonostia Institute. Patient inclusion will start in October 2019, and the results and conclusions are expected by July 2020.
The company has opened a funding round for its expansion and internationalization.
About Myogem
Myogem Health Company is a company founded in 2014 devoted to research, development and commercialization of food supplements and foods for special medical purposes to nutritionally manage and improve the quality of life of people affected by a rare disease.
Myogem was born as a result of a research project granted by Fundació la Marató de TV3 in the 2009 Rare Diseases call. In 2017, Myogem launched its first product, MYODM, as a food supplement specifically formulated from a unique combination of caffeine and theobromine that is not naturally present in any other food. Currently, MYODM is commercialized worldwide through the company, itself.
Please, contact us for more information:
Marta Pascual-Gilabert, Chief Scientific Officer and Project Coordinator; info@myogemhealth.com
 |
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875615. |
 |
Descargar nota de prensa Español |
|
Descarregar nota de premsa Català |
|
Download Press Release |
--------------------------------------------------------------------
